Mayo Clinic

Membership-based, non-insurance healthcare companies helping maintain a steady state of well being.

Preventive Healthcare

<div>
 
 AliveCor is an AI-enabled remote patient monitoring company that develops mobile electrocardiogram (ECG) devices that track users&rsquo; heartbeats under its flagship brand KardiaMobile.
 
 
 The FDA-approved solution is built on its proprietary technology, AI/ML-powered ECG sensors, and enables the detection of various cardiac conditions, such as atrial fibrillation, bradycardia, tachycardia, and sinus rhythm with supraventricular ectopy, in 30 seconds.&nbsp;
 
 
 The company&rsquo;s cardiological care subscription services include 1) KardiaCare, which offers heart health insights and monitoring features, including unlimited ECGs and clinician review at USD 11.99 per month, and 2) KardiaPlus, which extends the KardiaCare membership with additional reviews, a KardiaMobile 6L device, and blood pressure cuff.&nbsp;&nbsp;
 
 
 Key customers and partnerships
 
 
 As of January 2024, the company had served more than two million customers in over 40 countries.
 
 
 The company has several key partners. These include the following:&nbsp;
 
 
 - Clario to enable ECG readings to be collected from trial participants&rsquo; homes (
 <a href="https://sp-edge.com/updates/21063">
 August 2023
 </a>
 )
 
 
 - Thomas Jefferson University Hospital to evaluate the benefits of QTc monitoring with KardiaMobile 6L for patients receiving methadone maintenance therapy for opioid use disorder (
 <a href="https://www.prnewswire.com/news-releases/alivecor-and-thomas-jefferson-university-hospital-partner-to-evaluate-kardiamobile-6l-for-qt-prolongation-screening-in-patients-treated-for-opioid-use-disorder-301881575.html">
 July 2023
 </a>
 )
 
 
 - PaceMate to create an integrated system that will facilitate the collection and evaluation of ECG data (
 <a href="https://www.medicaldevice-network.com/news/cardiac-monitoring-pacemate-alivecor/">
 May 2023
 </a>
 )
 
 
 - BIOTRONIK to combine BIOTRONIK's injectable cardiac monitor with AliveCor's ECG technology (
 <a href="https://www.prnewswire.com/news-releases/biotronik-announces-collaboration-with-alivecor-as-first-in-a-series-of-strategic-partnerships-to-disrupt-cardiac-digital-health-with-ai-enabled-solutions-301620650.html">
 September 2022
 </a>
 )
 
 
 - GE Healthcare to integrate ECG data from AliveCor's KardiaMobile 6L device directly into GE Healthcare&rsquo;s MUSE Cardiac Management System for physicians to view and evaluate (
 <a href="https://www.businesswire.com/news/home/20220316005427/en/GE-Healthcare-AliveCor-Partnership-Aims-to-Increase-Convenience-for-Patients-and-Help-Reduce-Cardiac-Related-Hospitalizations-by-Improving-the-Quality-and-Integration-of-Patient-Data">
 March 2022
 </a>
 )
 
 
 - AstraZeneca to study disease management solutions using AliveCor&rsquo;s Kardia-K technology (
 <a href="https://sp-edge.com/updates/2136">
 February 2021
 </a>
 )
 
 
 Funding and financials
 
 
 In 
 <a href="https://sp-edge.com/updates/12459">
 August 2022
 </a>
 , the company raised an undisclosed amount in a Series F funding round led by GE Healthcare. The funds were aimed at advancing its cardiological care subscription services. 
 
</div>

Glooko is an app-based remote patient monitoring and diabetes management platform that collects patient data from a range of third-party glucose monitoring devices. Glooko’s US Food &amp; Drug Administration approved Mobile Insulin Dose Adjustment System (MIDS) allows healthcare providers to create customized care plans and provides patients with daily instructions on recommended insulin dosage levels based on the readings from the glucose monitoring devices.The platform also allows diabetic patients to track activity data and meals, access educational material, and follow care plans that are monitored through the app. As of March 2021, the app has partnered with more than 7,500 clinics and served 3 million users with diabetes across 27 countries.&nbsp;As of March 2022, the company had acquired two companies: 1) <a href="https://sp-edge.com/updates/8154">xbird </a>, a German AI-backed medical company, and 2) French diabetes care platform <a href="https://sp-edge.com/updates/9200?industryIds=22">DIABNEXT </a>as part of its planned global expansion drive. The integration of xbird’s Just In Time Adaptive Intervention technology will enhance Glooko’s advanced analytics capabilities and tools as well as expand its global reach across 7,500 clinics and more than one million users. DIABNEXT will be rebranded as Glooko XT and two platforms will be available for the French market which will allow the company to scale its operations into more regions and expand its remote patient monitoring services.Key customers and partnershipsIn <a href="https://sp-edge.com/updates/25233">January 2024</a>, the company partnered with Better Therapeutics to integrat Better Therapeutics' recently launched AspyreRx , a digital behavioral treatment for type 2 diabetes (T2D), into Glooko's platform.Funding and financials&nbsp;In March 2021, the company concluded a Series D round that brought its total funding up to USD 101 million to enter new geographical locations and expand its clinical product offerings to cover other chronic diseases.

Eko Health is a cardiopulmonary digital health company that aims to improve heart and lung care for patients using sensors and artificial intelligence. The company produces connected handheld digital stethoscopes with electrocardiogram (ECG) functionality to detect heart rhythm abnormalities using AI algorithms. The device also features noise cancellation and high-quality audio and color displays.&nbsp;In 2020, the company obtained FDA clearance for multiple algorithms that help detect heart murmurs and atrial fibrillation, or AFib. These algorithms were used in 2022 to develop the Eko App, which pairs to the company's stethoscopes for report generation, information sharing and carrying out examinations.The company operates on a fee per unit at USD 250-429 per device via a B2B2C model and a D2C model, where it provides its technology to healthcare providers and individuals for diagnostic purposes.Key customers and partnershipsIn <a href="https://sp-edge.com/updates/20215">July 2023</a>, the company partnered with pharmaceutical company Astellas to develop Z1608, a non-invasive device-DTx solution for heart failure patients.Funding and FinancialsIn <a href="https://sp-edge.com/updates/9283">March 2022</a>, raised a further USD 30 million in an extension to its Series C round, which began November 2020. These funds were used to support commercialization efforts and develop new products for the company. Further, in <a href="https://sp-edge.com/updates/13182">September 2022</a>, the company received its fourth small business innovation research grant of USD 2.7 million from the National Institutes of Health to develop an ML algorithm to detect pulmonary hypertension.

<div>
 
 Lucem Health offers a diagnostic platform, Lucem Health Reveal,&nbsp; designed to facilitate early detection of patients at a higher risk of severe or chronic illnesses, including diabetes, lower gastrointestinal disorders and prediabetes progression. The B2B-based company&rsquo;s AI models and algorithms use electronic health record data, including clinical data available in patient charts to provide predictive insights that can be integrated into existing clinical workflows. Unlike other AI solutions that focus on helping doctors, Reveal is designed to prioritize patient identification and care coordination without disrupting current workflows.&nbsp;
 
 
 The company also offers additional tools that support healthcare organizations deploy, monitor and improve their AI-powered solutions. Lucem was 
 <a href="https://sp-edge.com/updates/2170">
 launched in April 2021 by Mayo Clinic 
 </a>
 along with investing partners 
 <a href="https://sp-edge.com/companies/663000">
 Commure 
 </a>
 (a General Catalyst company) and Rally Ventures.&nbsp;
 
 
 Key customers and partnerships
 
 
 The company launched the Innovation Collaborative to create collaborations between AI developers and digital health innovators to develop new solutions to improve clinician decisions and support early disease detection. Some collaborative members include AI/ML developers AIQSolutions, AlgoDx, Cardiologs and CardioWise as well as digital health developers such as AvoMD, Brunswick MedTech, eCordum and NxgenPort.
 
 
 Funding and financials&nbsp;
 
 
 <a href="https://sp-edge.com/updates/18402">
 In May 2023
 </a>
 , the company raised USD 7.7 million in a Series A funding round led by Mayo Clinic. The funds were allocated&nbsp; towards advancing its platform for clinical AI solutions, expanding its range of solutions, and&nbsp; strengthening&nbsp; its sales and marketing efforts.
 
</div>

<div>
 
 Israel-based AI-powered population health management solutions provider Diagnostics Robotics offers care management programs that predict a patient&rsquo;s health risks to offer precise treatment and improve patient outcomes. The company claims customer satisfaction has improved by 93% while costs have declined by USD 150 per member.&nbsp;&nbsp;&nbsp;
 
 
 The program is built on engineered predictive models using data from tens of billions of claims data and around a hundred million patient visits. The proprietary program focuses on areas such as chronic care management, behavioral health, general risk and cost predictions, and personalized treatment plans for individuals. The company operates a B2B2C business model, offering services to payers, governments, providers, and employers. As of July 2022, the company had operations in the US and Israel.&nbsp;
 
 
 Key customers and partnerships
 
 
 In June 2021, the company partnered with insurance provider Blue Cross and Blue Shield of Rhode Island to provide personalized services to its members. In addition, as of June 2022, the company was working with government insurance programs Medicare and Medicaid to provide services to its members and reduce care costs effectively.&nbsp;
 
 
 Funding and financials
 
 
 The company raised USD 45 million in July 2022 in a Series B funding round led by StageOne investors, with participation from Mayo Clinic. The funds were allocated toward product development, market growth via investment in sales and marketing, and expansion to its human resources. In terms of its financial strength, the company&rsquo;s revenue has tripled YoY since 2020.&nbsp;
 
</div>

<div>
 
 Olive Diagnostics is an Israel-based startup, developing a passive remote monitoring device that can be mounted on any toilet to analyze urine in real time. The device, Olive KG, had received CE Marking from the EU, and, as of September 2022, had begun commercialization. As of February 2023, the company claimed the device was the world&rsquo;s first remote and non-invasive urine analysis.&nbsp;
 
 
 The Olive KG uses sensors and AI to detect key parameters of a patient&rsquo;s urine such as red blood cells, proteins, ketones, Nitrite, pH, volume, pressure, color, and frequency and sends real-time data to physicians. Furthermore, using AI algorithms and IoT technology, the device provides historical data, benchmarks, alerts on anomalies, and health insights focused on preventing and detecting diseases such as prostate, ovarian, kidney malignancies, heart failure, dehydration, kidney stones, and inflammation of the urine bladder.
 
 
 The company operates a B2B2C business model, providing the devices via healthcare providers and caregivers, primarily targeting elderly patients.&nbsp;&nbsp;
 
 
 Funding and financials
 
 
 The company raised USD 7.3 million in an extension to its seed funding round in September 2022.&nbsp;
 
</div>

<div>
 
 Theator is an AI-based surgical intelligence platform that aims to improve surgeon performance by leveraging computer vision technology, video analytics, and smart annotations to convert video data into actionable feedback. This allows surgeons to gain detailed insights and review an operation within minutes.&nbsp;
 
 
 Theator&rsquo;s dataset contains more than 30,000 hours of anonymized surgical video with a billion frames analyzed contributed by medical centers covering minimally invasive general surgery while also continuing to add specialties. Additionally, the software connects to hardware in an operating room and automatically uploads the video data to the cloud for post-op analysis. Founded in 2018, Theator was available in Israel, Canada and in the US as of July 2022. Initially used for education and training, the company now uses the technology for real-time decision support.&nbsp;
 
 
 Funding and financials
 
 
 The company received its most recent investment in July 2022 of USD 24 million as an extension to its Series A funding round, initially announced in February 2021, which brought total funds raised during the round to USD 39.5 million. The extension was led by Insight Partners with participation from several other new and existing investors including Mayo Clinic. The funds were allocated for expansions in commercial operations in North America, specifically in rolling out the platform in operating rooms and healthcare systems.
 
</div>

More important now than ever, telehealth will long outlast the pandemic that drove its growth.

Telehealth

<div>
 
 Glooko is an app-based remote patient monitoring and diabetes management platform that collects patient data from a range of third-party glucose monitoring devices. Glooko&rsquo;s US Food &amp; Drug Administration approved Mobile Insulin Dose Adjustment System (MIDS) allows healthcare providers to create customized care plans and provides patients with daily instructions on recommended insulin dosage levels based on the readings from the glucose monitoring devices. 
 
 
 The platform also allows diabetic patients to track activity data and meals, access educational material, and follow care plans that are monitored through the app. As of March 2021, the app has partnered with more than 7,500 clinics and served 3 million users with diabetes across 27 countries. As of March 2022, the company had acquired two companies: 1) 
 <a href="https://sp-edge.com/updates/8154">
 xbird
 </a>
 , a German AI-backed medical company, and 2) French diabetes care platform 
 <a href="https://sp-edge.com/updates/9200?industryIds=22">
 DIABNEXT
 </a>
 as part of its planned global expansion drive. The integration of xbird&rsquo;s Just In Time Adaptive Intervention technology will enhance Glooko&rsquo;s advanced analytics capabilities and tools as well as expand its global reach across 7,500 clinics and more than one million users. DIABNEXT will be rebranded as Glooko XT and two platforms will be available for the French market which allow the company to scale its operations into more regions and expand its remote patient monitoring services.
 
 
 Founded in 2010, Glooko is headquartered in both California and Sweden. In March 2021, the company concluded a Series D round that brought its total funding up to USD 101 million to enter new geographical locations and expand its clinical product offerings to cover other chronic diseases. 
 
</div>

<div>
 
 Abridge is an AI-focused company that provides automated note-taking solutions for healthcare providers. It uses its medical conversation AI, a dataset of 1.5 million medical encounters, and peer-reviewed research to provide this solution. As of August 2022, Abridge has worked with over 2,000 clinicians and 200,000 patients. The company also has several current and upcoming partnerships with healthcare providers across the value chain from payers to pharmacies to Fortune 5 healthcare companies.
 
 
 
 
 Key customers and partnerships
 
 
 In March 2024, Abridge partnered with n
 ot-for-profit health system Sutter Health, to implementing Abridge&rsquo;s AI platform for clinical documentation across Sutter's network in California. 
 
 
 Funding and financials
 
 
 In February 2024 Abridge raised USD 150 million in a Series C funding round co-led by Lightspeed Venture Partners and Redpoint Ventures. This brought the company's valuation to around USD 850 million. The raised capital was set aside for recruitment and the acquisition and training of bespoke medical AI models.
 
 
 
</div>

<div>
 
 Lisa Health is a women-focused digital health startup has developed an app for menopausal care called Midday. The app can be used to track, treat, and consult specialists regarding menopause symptoms. Additionally, the app provides educational content and tailored insights, healthy aging recommendations, and suggestions for treating symptoms. The app uses an algorithm to determine which stage of menopause the user is in and prepares them for symptoms in the next stage.&nbsp;
 
 
 
 
 As of August 2022, the app works on a subscription basis and offers two options, a three month subscription for USD 29.99 and an annual subscription for USD 77.99.
 
 
 
 
 Key customers and partnerships
 
 
 In August 2022, the company 
 <a href="https://sp-edge.com/updates/12060">
 partnered with Mayo Clinic to launch its Midday app
 </a>
 . Through the partnership, Lisa Health gained access to Mayo Clinic&rsquo;s team of clinical expertise on menopausal care. These clinicians were also part of the app&rsquo;s development process and ensure the app uses current evidence-based approaches.&nbsp;
 
 
 Funding and financials
 
 
 In August 2022, the company raised USD 2.5 million in an oversubscribed seed round led by Radical Ventures. Mayo Clinic also participated in the round.
 
 
 
</div>

<div>
 
 Eko Health is a cardiopulmonary digital health company that aims to improve heart and lung care for patients using sensors and artificial intelligence. The company produces connected handheld digital stethoscopes with electrocardiogram functionality to detect heart rhythm abnormalities using artificial intelligence (AI) algorithms. In 2020, the company obtained 501(k) FDA clearance for multiple algorithms that help detect heart murmurs and atrial fibrillation, or AFib. These algorithms were used in 2022 to develop the Eko App, which pairs to the company's stethoscopes for report generation, information sharing and carrying out examinations. 
 
 
 The company operates on a fee per unit B2B2C model and a D2C model, where it provides its technology to medical practitioners or patients for diagnostic purposes.
 
 
 In February 2023, Eko 
 <a href="https://sp-edge.com/updates/16677">
 launched SENSORA
 </a>
 , a cardiac disease detection platform that combines the company&rsquo;s existing digital stethoscopes with a machine learning-based platform. The platform enables primary care physicians to detect structural murmurs and assess heart arrhythmias by using a database of heart sounds to compare and identify anomalies in a patient's heart beat. 
 
 
 In April 2024, Eko 
 <a href="https://sp-edge.com/updates/28111">
 obtained FDA 510(k) clearance
 </a>
 for its AI-aided cardiac tool, Eko Low Ejection Fraction Tool (ELEFT). The tool is designed to assist providers in early detection of low ejection fraction, a significant sign of heart failure.
 
 
 Funding and financials
 
 
 In March 2022, raised a further USD 30 million in an extension to its Series C round, which began November 2020. The total funds raised by the company stood at USD 126 million as of March. These funds have been allocated to support further commercialization efforts and develop new products for the company.
 
 
 
 
 
 
 
</div>

<div>
 
 GYANT is a 24/7 AI chatbot for triage and diagnosis. The chatbot asks patients a series of questions about symptoms which are interpreted using natural language processing to determine an appropriate course of action. The chatbot can also provide answers to queries, leave prescription refill requests, and direct patients to a telehealth or in-patient booking system.&nbsp;
 
 
 Founded in 2016, the company configures its solutions to integrate with a provider's digital tools, clinical endpoints, electronic health record systems, website, patient portal, branding, and mobile app.&nbsp;
 
 
 GYANT&rsquo;s customer base grew to 24 healthcare systems as of July 2020 compared to 9 in July 2019. In July 2020, Gyant raised a Series A funding round that brought total funding to USD 22.8 million.
 
</div>

Technologies bringing about a new reality

Extended Reality

VMocion develops tech to mitigate cybersickness, using its proprietary 3V and WAIV products. 3V, developed in collaboration with Mayo Clinic simulates physical motion for users in virtual, augmented, and mixed reality environments. This is achieved through its WAIV algorithm, which connects to wearable contact points. The technology eliminates motion sickness by sending impulses to the ear's vestibular system, which regulates balance and spatial orientation in the human body.The company provides a license, reference designs, circuitry, and an SDK to integrate its solutions into head mounted displays (HMDs) such as VR/AR headsets, stereo headphones, and flight simulations. Other applications of 3V include video game consoles, smartphones, and other digital devices. Additionally, its WAIV algorithm can be used to prevent motion sickness in self-driving vehicles, rides at amusement parks, cruise ships, and train rides.Funding and financialsIn January 2024, VMocion raised USD 3 million in a seed funding round, with participation from AZ Crown and Mayo Clinic.&nbsp;The funds were earmarked to further progress its technology, with Eric Crown of Insight Enterprises also joining the company’s board, alongside VMocion principals and Mayo Clinic.Competitors: None under coverage (VMocion develops products to mitigate cybersickness in XR environments.)

FundamentalVR is the provider of the “Fundamental Surgery,” a VR surgical simulation software that enables remote proctoring with unlimited multi-user collaboration capabilities to educate, train, and assess surgical skills of medical professionals. The platform has multiple modes of access including standalone headsets, such as Meta Quest headsets and tethered VR setups.It also offers training modules in medical areas such as orthopedic, spine, ophthalmology, urology, robotics, and endovascular training. FundamentalVR’s patented haptic systems (“HapticVR”) deliver users the full sense of force-feedback touch, enabling procedural rehearsal in deep simulation with precise measurements. StandAloneVR, the variant of the platform for standalone devices, enables procedural walk-throughs, anatomy and environment familiarization, and testing. HapticVR and StandAloneVR are both supported by a data dashboard backed by AI and machine learning technologies to provide real-time training records and insights on user knowledge and skills.In May 2023, the company launched the Fundamental Core SDK, allowing developers to create and distribute their own surgical and medical simulations. This includes the creation of multi-user and haptic feedback enabled experiences.The company charges a one-time fee for the hardware equipment and an ongoing licensing fee for its platform. As of February 2022, Fundamental Surgery claims to be the only education platform that is fully accredited by the American Academy of Orthopaedic Surgeons (AAOS) and the Royal College of Surgeons.Key customers and partnershipsThe company’s clients include Pearson (a UK-based multinational publishing and education company), Novartis (a Swiss multinational pharmaceutical company), Boston Scientific (a leading medical device manufacturer), and Orbis (a non-profit organization focused on fighting avoidable blindness). Notable backers of FundamentalVR include leading US-based medical center operator Mayo Clinic and Sana Kliniken, Germany’s third-largest private hospital group.Funding and financialsThe company raised USD 20 million in a Series B funding round led by EQT Life Sciences in <a href="https://sp-edge.com/updates/12279">August 2022</a>. The fresh funds were earmarked for its expansion across the US and product development initiatives.

Medivis is a medtech company that offers two key AI-backed AR platforms; (1) SurgicalAR for surgical imaging and (2) AnatomyX, an AR anatomy lab and learning platform.SurgicalAR is an AR platform that overlays 3D images onto a patient's body, aiding in the precise planning of procedures across medical fields such as neurosurgery, orthopedics, and reconstructive surgery. The platform's ability to render patient-specific MRI and CT imaging holographically provides a view of the patient's internal anatomy, being able to process any patient's data in 10 seconds or sooner, applicable in areas like oncology, trauma, vascular anomalies, and congenital malformations. The system operates on Microsoft’s HoloLens 2 headset, with the platform's hand gestures enabling users to manipulate patient data through the use of hand tracking, erasing, painting, cutting planes, cropping, window sliders, brush tools, and more.The company offers two workstation solutions: the SurgicalAR PRO Workstation and the SurgicalAR Mini Workstation. The PRO Workstation, designed for operating room applications features a 32” multi-touch display and is an FDA-approved solution with integrated hardware for holographic rendering of patient-specific data.The Mini Workstation, intended for ICU and bedside procedures, is a compact, FDA-approved solution that integrates a multi-touch 17" display.&nbsp;AnatomyX is an AR and spatial computing software designed to enhance learning outcomes and engagement in educational institutions. The software is compatible with HoloLens 2 and Magic Leap’s headsets and features 5,000+ detailed anatomy models, each designed in-house in 3D to meet industry standards. Key platform features include multi-user sharing capabilities, which allows for a shared AR learning experience; anatomy information, with models supported by up-to-date facts and figures about anatomy functions, and a custom learning portal that allows users to create classrooms, assign instructors, construct quizzes, and review students' progress in a central location. In a term test carried out, the company noted that students using the software reported a one to two-letter grade improvement, with 95% stating that their learning was enhanced.&nbsp;As of January 2024, Medivis noted that multiple additional features for its platform were under development. These include a holographic cranial navigation system that uses three registration techniques to align CT and MRI imaging with a patient's body (in&nbsp; beta); a Spine Navigation system to assist surgeons in placing pedicle screws and interbody devices; and an ultrasound AR software for patient body imaging.Key customers and partnershipsAs of January 2024, 500+ surgeries were planned and rehearsed through its SurgicalAR platform, having been deployed in 40+ hospitals and medical schools.&nbsp;Key institutions include Veterans Health Administration, Lenox Hill, MD Anderson, UPMC, and Swedish Providence Neuroscience Institute. Additionally, the company’s AnatomyX platform recorded 40+ institutions with 2,000+ active users.In February 2020, Medivis partnered with the US Department of Veterans Affairs (VA), Verizon, and Microsoft to deliver the VA’s first 5G-enabled, clinical care system at the VA Palo Alto healthcare system.Funding and financialsIn June 2023, Medivis raised USD 20 million in a Series A funding round led by Thrive Capital. Funds raised will be used to scale the company's engineering efforts, obtain necessary regulatory clearances, and commercialize its technology globally across multiple specialties.

MediView is a MedTech company that leverages AR, telecollaboration, and data-driven insights to improve diagnostic imaging, surgical navigation, and clinical efficiencies. MediView's remote connectivity enables medical professionals to connect and collaborate remotely through shared communication, visualization, and holographic guidance. Moreover, MediView records the data generated during holographic procedures to provide insights to medical professionals. In addition, Mediview offers a training environment for students at sonography and echo programs, nursing schools, physician assistant schools, medical schools, and veterinary schools.The company provides three solutions, MediScout (XR30), MediView XR50, and MediView XR90, at various stages of development. MediScout is a commercially available FDA Class I medical device, offering a collaborative and ergonomic ultrasound imaging solution. The XR50, to be submitted for FDA clearance, is an ultrasound imaging solution for needle-based procedures. The XR90, MediView's flagship product, is an FDA cleared imaging and navigation system for soft tissue and bone procedures, providing a clear view of the patient's internal anatomy via holographic surgical navigation (3D x-ray vision). In March 2024, a study published on the Journal of Medical Imaging found the XR90 accurate enough to carry out procedures with clinical precision.Key customers and partnershipsMediView provides its solutions in partnership with GE Healthcare and Microsoft by integrating Microsoft's HoloLens 2 head-mounted display and GE's Vivid iq ultrasound system. In November 2022, Mediview collaborated with GE to develop the OmnifyXR Interventional Suite System, which is intended to improve ergonomics with natural interactions for optimum workflow and facilitate care team cooperation.Funding and financialsIn <a href="https://sp-edge.com/updates/18603">May 2023</a>, the company raised USD 15 million in a strategic funding round with participation from Mayo Clinic, Cleveland Clinic, and GE HealthCare, among others. Funds were earmarked to create and enhance the company’s multi-level platform, prioritizing activities such as generating more clinical evidence, developing new products, protecting intellectual property, meeting regulatory requirements, achieving commercial goals, and launching new products.

Pushing the envelope in MedTech with emerging technologies

Next-gen Medical Devices

<div>
 
 Eko is a digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its suite of AI-powered digital tools. Its FDA-cleared technology is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect disease earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko is headquartered in Oakland, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others.
 
 Eko exists to ensure all patients have access to early heart and lung disease detection that improves and extends their lives.
 
</div>

Automation in clinical diagnostics to improve speed and accuracy in patient diagnosis and treatment.

Clinical Decision Support Systems

<div>
 
 Ambient Clinical Analytics is the creator of a software platform designed for data assimilation, communication and analytics. It is based on decision support tools initially deployed in the intensive care unit (ICU) or emergency department of hospitals. Our software consists of algorithms that mine data from electronic medical records (EMR). Itthen presents that data to the physicians and nurses so they may facilitate real-time clinical decision making and care delivery. These products are positioned as add on applications that are designed to easily integrate with the current major EMR providers.
 
</div>

Simplifying healthcare administration with intuitive tech tools

Hospital Management

<div>
 
 GYANT is a digital front door solution for health systems that uses AI to navigate patients to the right care setting and relevant in-network resources. GYANT helps health systems implement digital patient journeys to effectively capture new patients, efficiently serve existing ones, and drive process automation across the enterprise.
 
</div>

<div>
 
 Abridge is a medical conversation AI startup that offers an audio-based system to record and summarize medical conversations. It was created for everyone, with a mission to help better understand their health conversations, whether at home or in the hospital. It was incorporated in 2018 and is based in Pittsburgh, Pennsylvania.
 
</div>

Redefining hospital care with the comfort of home

Hospital-at-Home

<div>
 
 Medically Home is a tech-enabled clinical enterprise that provides all the necessary capabilities to safely-shift medical care from hospitals to patients&rsquo; homes. Its platform offers a virtual hospital program that connects patients with caregivers and supports the monitoring of, and communication with patients with high acuity illness that helppatients and their families to access a medical command center that provides centralized, on-demand acute medical care management from the comfort of their homes.
 The company was founded in 2016 and is headquartered in Boston, Massachusetts.
 
</div>

Using data and automation to achieve 24/7 production.

Smart Factory

<div>
 
 Founded in 2022, Collaborative Robotics is a developer of collaborative robots (cobots). The company is developing a collaborative robotic arm with six degrees-of-freedom (DOF), which will serve the market between high-end robots (like Tesla&rsquo;s Optimus) and basic autonomous mobile robots (AMRs). The company claims that its collaborative 6DOF robotic arm, which will work alongside humans, will be a novel offering in the market. The cobot will be developed to perform various tasks, targeting the manufacturing, logistics, agriculture, healthcare, and hospitality industries. Collaborative Robotics was founded by former Amazon Robotics (developer of robotic systems for automated fulfillment at Amazon fulfillment centers and warehouses) Vice President Brad Porter.
 
 
 Funding and financials
 
 
 In June 2022, Collaborative Robotics raised USD 10 million in Seed funding to come out of stealth. The round was led by Neo with participation from Khosla Ventures, Calibrate Venture Capital, and 1984 Ventures. The funds were used to invest in R&amp;D, develop the company&rsquo;s infrastructure, and to fill strategic positions to grow headcount from to around 20 to 25 employees.
 
 
 <a href="https://sp-edge.com/updates/20459">
 In July 2023
 </a>
 , Collaborative Robotics raised USD 30 million in a series A funding round. The funding was led by Sequoia Capital with participation from Khosla Ventures, Mayo Clinic, Calibrate, Neo, and 1984.vc. With the new funding, the company planned to initiate the scaling process for early field deployments and commence the manufacturing of its collaborative robot (Cobot).&nbsp;
 
 
 
 
</div>

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

<div>
 
 SimBioSys is a precision medicine company leveraging the power of AI, data science, and spatial biophysics to transform patient care and combat cancer. The company specializes in creating detailed 3D models of tumors through its TumorSight Viz &amp; Plan, TumorSight IQ, and PhenoScope solutions, designed to deliver precise answers to critical clinical questions and personalize patient treatment. These technologies address the diverse responses to treatment caused by tumor heterogeneity by examining the tumor, moving beyond traditional biopsies or 2D pathology slides.
 
 
 In 
 <a href="https://simbiosys.com/2024/01/19/simbiosys-elevates-leadership-team-as-it-receives-first-fda-clearance-for-digital-precision-medicine-platform-tumorsight/">
 January 2024
 </a>
 , the company received FDA clearance for its digital precision medicine platform, TumorSight. This approval is expected to enhance the company's credibility and expand its market reach, thereby benefiting a broader spectrum of patients and healthcare providers by offering insights into precision medicine in cancer care​.
 
 
 
 
 
 Key customers and partnerships
 
 
 
 
 SimBioSys entered partnerships with over 40 organizations, including 
 <a href="https://sp-edge.com/updates/25163">
 Mayo Clinic
 </a>
 , Cleveland Clinic, Cedars Sinai, and the University of Chicago Medicine. These partnerships were part of SimBioSys' broader efforts to validate and enhance the efficacy of its solutions in addressing cancer treatment's complexities.
 
 
 
 
 
 Funding and financials
 
 
 
 
 On October 26, 2021, SimBioSys raised USD 15 million in a 
 <a href="https://sp-edge.com/updates/6245">
 Series A funding
 </a>
 round co-led by Genoa Ventures and Northpond Ventures. SimBioSys intended to use these funds to expand its technology into other solid tumors beyond breast cancer and to drive commercialization efforts to bring the technology to patients and the biopharma industry. 
 
</div>

New data privacy regulations have opened up space for a new wave of compliance-focused startups.

Digital Privacy Tools

<div>
 
 TripleBlind helps organizations process and collaborate using sensitive data in an encrypted space without compromising privacy. The company&rsquo;s patented products encrypt data during the upload process while its digital rights management and auditing tools control and monitor data access; enabling enterprises to comply with privacy regulations such as GDPR and other industry-specific privacy requirements in the financial services and healthcare sectors.
 
 
 TripleBlind emerged from stealth in November 2020 following a pre-seed funding round from Accenture. In October 2021, the company raised USD 24 million in an oversubscribed Series A funding round co-led by General Catalyst and Mayo Clinic.
 
</div>

AI-based solutions for evolving digital threats

Next-gen Cybersecurity

<div>
 
 Ordr provides an AI-based system control engine that leverages deep packet inspection and advanced machine learning to help organizations secure IT, Internet of Medical Things (IoMT), Internet of Things (IoT), and Operational Technology (OT) devices in their environment. The company leverages insights to provide real-time granular asset visibility, enforce zero-trust policies, and automate incident response for compromised devices, risks, and behaviors. Ordr provides threat and ransomware detection and response to secure an organization&rsquo;s attack surface against risks associated with data breaches, ransomware, lateral movement, and more.
 
 
 Ordr Clinical Defender uses deep packet inspection, API integrations, and application decoding techniques to automatically discover, classify, and provide context on connected medical devices. The device context is combined with insights from network topology, Active Directory, and threat intelligence to profile connected device behaviors and risks. It leverages advanced machine learning (ML) to create behavior baselines for each individual device and automates actions on networking and security infrastructure. The platform protects devices with proactive and reactive policies such as quarantining devices, blocking traffic, terminating sessions, or by implementing zero trust segmentation.
 
 
 Key customers and partnerships
 
 
 Ordr serves customers in the healthcare, manufacturing, retail, government, education, and extended enterprise IoT sectors. Notable customers include ProHealth Care, Mayo Clinic, Cleveland Clinic, Nexteer Automotive, and Cook Children's Health Care System.
 
 
 Funding and financials
 
 
 Ordr experienced over 140% YoY growth in new customer revenue for the quarter ended March 2022. As of June 2022, the company served more than 500 customers, which included federal, state, and local governments. The platform is deployed in three of the top six global hospitals and in more than 150 manufacturing sites.
 
 
 In June 2022, the company 
 <a href="https://sp-edge.com/updates/10846">
 raised USD 40 million
 </a>
 in a Series C funding round, co-led by Battery Ventures and Ten Eleven Ventures. The funds were expected to be utilized to accelerate its sales and marketing efforts, especially in vertical markets such as healthcare, manufacturing, and financial services, expand its channel and partnership programs, invest in customer success, expand integrations with leading security solutions, and double its employee headcount of 80 across the marketing, customer success, and engineering departments during 2023.
 
</div>

Using AI to mimic and understand human language

Natural Language Processing Tools

Radioactive materials open up new pathways in patient treatment and medication

Radiopharmaceuticals

<div>
 
 Nucleus RadioPharma is a new company that was founded to ensure that cancer patients have access to potentially life-saving radiopharmaceuticals by developing technologies to modernise the clinical development, manufacturing, and supply chain of these promising new therapies.
 
</div>

Exploring the limitless possibilities of AI

Generative AI Applications

<div>
 
 Abridge is a provider of healthcare conversation solutions enabling clinicians to focus more on patient care by improving clinical documentation efficiencies. It converts patient-clinician interactions into structured clinical notes, enhancing clinical documentation by ensuring accuracy and efficiency. This also encompasses the &quot;Linked Evidence&quot; feature, which correlates AI-generated summaries with the original data, improving trust and verification of the AI&rsquo;s output.
 
 
 
 
 Key customers and partnerships
 
 
 
 
 Abridge has fortified its presence in the healthcare sector through a partnership with Yale New Haven Health System, aiming to deploy its AI technology for clinical documentation across the system's network. In March 2024, the company partnered with 
 <a href="https://sp-edge.com/updates/27571">
 UCI Health,
 </a>
 the healthcare system of the University of California, Irvine, to optimize documentation and improve operational efficiency for their clinicians.&nbsp;
 
 
 
 
 In March 2024, Abridge partnered with
 <a href="https://sp-edge.com/updates/27751">
 NVIDIA
 </a>
 for resources and expertise to develop AI systems for clinical documentation and improve medical care.
 
 
 
 
 Funding and financials
 
 
 
 Abridge raised 
 <a href="https://sp-edge.com/updates/26939">
 USD 150 million
 </a>
 in a Series C funding led by Lightspeed Venture Partners and Redpoint Ventures in February 2024 to develop foundational models by leveraging large volumes of multimodal healthcare data. In March 2024, it received an undisclosed amount from NVentures, NVIDIA's venture capital division. 
 
</div>

Longevity Tech

<div>
 
 UNITY Biotechnology develops therapeutics targeting age-related diseases, particularly focusing on therapy in ophthalmologic diseases, including diabetic macular edema and age-related neurologic conditions.
 
 
 
 
 Its therapeutics are intended to selectively eliminate or modulate senescent cells to slow down, stop, or even reverse age-related disease and restore aging or damaged tissue to a more functionally healthy state. The approach is expected to remedy diseases of aging, such as retinopathies, neurodegenerative disorders, fibrosis, and cancer.&nbsp;
 
 
 
 
 The company&rsquo;s lead drug candidate, UBX1325, is evaluated for the treatment of age-related diseases of the eye, including diabetic macular edema. The small molecule targets Bcl-xL, a protein that senescent cells rely on for survival. It is claimed that UBX1325 demonstrated a statistically significant and clinically meaningful improvement in mean best corrected visual acuity (BCVA) across 48 weeks compared to sham treatment in the Phase II BEHOLD study in patients with DME. A Phase IIb study (ASPIRE) was enrolling patients with DME to evaluate UBX1325 head-to-head against aflibercept.
 
 
 
 
 UNITY Biotechnology was also developing programs targeting the Tie2 signaling pathway for therapeutic benefit. Tie2 pathway activity declines with age and causes the loss of vascular barrier integrity and diseased blood vessel formation in the eye. The Tie2/VEGF bispecific molecule targets two pathways believed to be core to disease progression in DME and AMD. Another program directed at Tie2 activation is in preclinical studies for multiple indications.
 
 
 
 
 The company's neurology programs intend to explore new mechanisms for cognitive benefit, and the company licensed its &alpha;-Klotho program, UBX2089, to Jocasta Neuroscience for development and commercialization in cognitive dysfunction associated with neurological and psychiatric conditions.
 
 
 
 
 
</div>

Collaborative Robotics is a team of innovators and builders redefining the future of human-robot interaction. A future in which robots are trustworthy extensions of the environment. They operate, adapt, and react in response.

UpDoc is a technology-enabled services firm that offers the world's first unique conversational AI platform for autonomous prescription management.

vMocion, LLC is a Media and Entertainment company that holds the exclusive, global, perpetual license for Mayo Clinic’s Galvanic Vestibular Stimulation (GVS) patents and algorithms within all media and entertainment categories.  The company was formed by Hillstrom Media Technology, LLC (HMT) and  Mayo Clinic to create vMocion’s 3v™ Platform, which can be licensed and integrated into a variety of media and entertainment applications, including virtual reality (VR) and augmented reality (AR) platforms.

Abridge is a medical conversation AI startup that offers an audio-based system to record and summarize medical conversations. It was created for everyone, with a mission to help better understand their health conversations, whether at home or in the hospital.

Nucleus RadioPharma is a new company that was founded to ensure that cancer patients have access to potentially life-saving radiopharmaceuticals by developing technologies to modernise the clinical development, manufacturing, and supply chain of these promising new therapies.

InfoBionic transforms the efficiency and the economics of ambulatory remote patient monitoring processes and cardiac diagnostic services by optimizing clinical and real-world utility for the users that need it most – physicians and their patients. It has developed the MoMe System, a remote patient monitoring platform initially focused on cardiac arrhythmia detection, to improve clinical efficiency and patient care with any time, anywhere access to patient data.

AccuLine is a digital healthcare company, which was founded with the vision to saves the lives of millions of people worldwide, by preventing the next heart attack. AccuLine is developing CORA— a smart, accurate, and easy to use exam for the early detection of coronary artery disease.

Contract Network is a developer of a digital collaborative platform for clinical trials. Its platform focuses on radically accelerating contract negotiations, simplifying contract compliance, and accelerating the negotiation of clinical trial agreements.

Basys.ai automates the process of prior authorization and utilization management to improve costs and timeliness for health plans/payers using an AI-based platform. The proprietary platform automates the process of encoding/digitizing the payer policies using machine learning, thus reducing the piloting timeline by up to 9 months.

EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware and software components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.

Medivis manufactures Software as a Medical Device (SaMD) for augmented reality surgical navigation. The company was founded in 2016 and is headquartered in the Flatiron district of New York City.

MediView XR is a MedTech company developing augmented reality x-ray vision for surgery, remote collaboration, and data-based insights. The company also designs intellectual property in development of Extended Reality Surgical Navigation with intended use in the ablation and biopsy of cancerous tumors.

Lucem Health develops a remote diagnostics platform designed to connect remote patient telemetry and biosensing devices with AI algorithms. Lucem's platform focuses on data ingest, orchestration, and connectivity, enabling clinicians to provide more effective continuous care and empower consumers to have better control of their health and well-being.

Medi Whale seeks to achieve sustainable healthcare where every eye can truly be the window to one’s health with our world's first-of-its-kind 1-stop AI screening platform solution for cardiovascular, renal, metabolic risk assessment, and eye disease diagnosis.  Our AI Platform was developed through several clinical collaborations (Korea, Singapore, India, UK, and other European datasets) using structured longitudinal event-based datasets for the development of our retinal biomarker engines.  RetiCVD® (cardiovascular disease risk assessment): Developed using coronary artery calcium (CAC) score, CAC is recognized as the gold standard for precise CVD risk calculation. Our CVD engine predicts the presence of CAC and provides a stratified probabilistic risk based on US ASCVD and EU SCORE guidelines. RetiCKD® (chronic kidney disease risk assessment): Developed using eGFR and full lab panel, our CKD engine has been demonstrated to achieve better predictive capability as compared to eGFR or full panel analysis. RetiEYE®: Referable Eye Disease engine detects and flags common aging-related eye modalities such as diabetic retinopathy, age-related macular degeneration, glaucoma, and cataract at its referable disease state. Medi Whale retinal-based systemic biomarkers have been clinically demonstrated to be non-inferior to current gold standards and are recognized by clinical and scientific communities with two Lancet Digital Health publications.

Cadence Neuroscience is an early-stage company developing new medical device therapies for the treatment of epilepsy, central pain, and other neurological disorders. The company's core technology has been developed at Mayo Clinic and is under clinical evaluation. Its medical device therapies provide medical practitioners with a procedure that can be used to tailor brain stimulation therapy to each individual and enhance seizure control compared to currently used protocols.  Cadence Neuroscience was established in 2017 and is headquartered in Redmond, Washington.

Healium is a drugless solution for the self-management of anxiety and sleep and the technology that connects fitness trackers to video assets. It's the world's first reactive, immersive media channel powered by the user's brainwaves and heart rate via smart watches, EEG meditation headbands, or other sensors they already have in their homes. In 8 peer-reviewed journals, Healium has been shown to quickly reduce anxiety, improve mood, or increase feelings of positivity in as little as four minutes. These data-driven video escapes are controlled by the user's bio-data displayed on the screen via hardware-agnostic sensors

R-Zero is a biosafety technology company dedicated to making indoor spaces they share safer, healthier, and more productive. R-Zero’s intelligent biosafety technology platform provides visibility, automation, and risk reduction within the indoor spaces.

Acorai is building a non-invasive heart failure monitoring platform with direct intracardiac pressure monitoring (ICPM) at its core. Acorai offers accurate and cost-efficient heart failure care using patented technology that leverages a novel combination of sensor technologies and machine learning to enable non-invasive ICPM, the only proven way to improve outcomes in HF patients. The device has been clinically validated, designated FDA Breakthrough Device and will be entering the market in 2025.  Acorai is a MedTech company with HQ in Sweden. The company has 20 FTE across 12 countries, with offices in Sweden and the UK.

Genomadix develops molecular tests in the areas of infectious disease, precision medicine, and water safety testing.

Senda Biosciences is a developer of therapeutic applications intended for novel treatments of human disease. The company studies the molecular relationships between bacterial, botanical, and human cells as well as how they define health and disease, providing medical professionals with novel medications and delivery methods. Senda Biosciences was established in 2017 by David Kolesky, Ignacio Martinez, and John Casey in Cambridge, Massachusetts.

Diagnostic Robotic develops a signal-agnostic artificial intelligence system for healthcare insurers, providers, and patients. It allows building powerful predictive analytics models that will solve a world-wide challenge, strained health budgets, and workforces. Diagnostic Robotic was founded on 2017 and is headquartered in Tel Aviv, Israel.

Midday is an app that leverages AI, sensor technology, and digital therapeutics to support women on their menopause journey using personalized insights that illuminate what is happening physically and emotionally during menopause, providing the right intervention at the right time to manage menopause symptoms and promote healthy aging.

Ordr makes it easy to secure every connected device, from traditional IT devices to newer and more vulnerable IoT, IoMT, and OT. Ordr uses deep packet inspection and advanced machine learning to discover every device, profile its risk and behavior, map all communications and protect it with automated policies. Organizations worldwide trust Ordr to provide real-time asset inventory, address risk and compliance and accelerate IT initiatives. Ordr is backed by top investors including Battery Ventures, Wing, and TenEleven Ventures.

It's About me (IAM) has developed a passive sensor mounted to the rim of the toilet that performs urinalysis every time the end-user urinates.  The information is uploaded to a robust data science platform to track existing and progressing conditions. Real-time, actionable notifications will be sent to the end user for proactive medical or nutritional care. Ongoing biomarker tracking for hydration, Alcohol, Pregnancy, Ovulation, Keytones, etc. is used to develop a comprehensive personal user profile. The technology will also be used for pharma and CRO companies to track the usage of drugs. While drug compliance issues plague health care systems around the world, I AM's technology will provide a reliable and continuous solution for tracking when and how people take their medicine or clinical trial drug. Nonindustrial nations will now have home access to urine lab services.

Karkinos Healthcare is technology-driven oncology focussed managed health care platform for the early detection and diagnosis of common cancers.

Vyriad is a clinical-stage company developing proprietary oncolytic virus therapies for the treatment of cancers with significant unmet needs. The potentially life-changing oncolytic viral technologies of Vyriad are the result of decades of research by dedicated researchers and clinicians at Mayo Clinic and the University of Miami.

Theator is a surgical intelligence platform that combines artificial intelligence and computer vision to improve surgeon performance. Its platform is powered by Visual AI that puts defining intraoperative moments in the hands of surgeons so they can continuously perfect their craft. Theator is partnering with visionary surgeons and hospitals to help create a more transparent OR while empowering surgeons to raise their expertise to the highest possible level.

Collider activates, connects, and empowers early-stage entrepreneurs in Rochester, Minnesota.

Medically Home is a tech-enabled clinical enterprise that provides all the necessary capabilities to safely-shift medical care from hospitals to patients’ homes. Its platform offers a virtual hospital program that connects patients with caregivers and supports the monitoring of, and communication with patients with high acuity illness that help patients and their families to access a medical command center that provides centralized, on-demand acute medical care management from the comfort of their homes. The company was founded in 2016 and is headquartered in Boston, Massachusetts.

SimBioSys is developing a Computational Microscope that integrates state-of-the-art simulation techniques with a diverse set of experimental datasets to provide new insight into the behavior of cancers. The technology allows researchers to peer into the cancer microenvironment to identify the behavior of tumors: the cell phenotypes, how they interact with surrounding tissues, and how they prime their neighbors for invasion, all from the comfort of their computer desk.

TripleBlind has created the most complete and scalable solution for privacy enhancing computation. The TripleBlind solution is software-only and delivered via a simple API. It solves for a broad range of use cases, with current focus on healthcare and financial services. The company is backed by Accenture, General Catalyst and The Mayo Clinic. TripleBlind’s innovations build on well understood principles, such as federated learning and multi-party compute. Our innovations radically improve the practical use of privacy preserving technology, by adding true scalability and faster processing, with support for all data and algorithm types. TripleBlind natively supports major cloud platforms, including availability for download and purchase via cloud marketplaces. TripleBlind unlocks the intellectual property value of data, while preserving privacy and ensuring compliance with HIPAA and GDPR.  TripleBlind compares favorably with other privacy preserving technologies, such as homomorphic encryption, synthetic data, and tokenization and has documented use cases for more than two dozen mission critical business problems.

Laplace is a medical device company that develops transcatheter tricuspid valve technology. The company's transcatheter tricuspid valve technology offers an increase in life expectancy and an improvement to the quality of life to worldwide patients with tricuspid regurgitation.

Adaptive Phage Therapeutics provides therapeutic services intended to treat multi-drug resistant pathogenic bacteria. Its services are provided using clinical and therapeutic technology that matches phages to patient-specific bacterial infections, enabling medical researchers to develop drugs that can detect and eliminate multi-drug resistant bacteria.

Glooko develops a remote patient-monitoring platform to identify at-risk patients with diabetes. It integrates with diabetes devices, fitness wearables, and activity trackers to allow data capture and provide reports and analytics that aim to drive behavior change and outcomes.

Nuvolo is an EAM platform that delivers a simple, intuitive, and user-friendly online and offline mobile experience. It is revolutionizing enterprise asset management by innovating on ServiceNow, an enterprise cloud platform. The company’s vision is to be the global leader in cloud-based EAM, powered by a culture of innovation and a relentless commitment to customer service. Fully optimized for growing, mobile workforces worldwide, Nuvolo delivers a simple, intuitive, and user-friendly online and offline mobile experience.  It was founded in 2013 and is headquartered in Paramus, New Jersey with offices throughout the U.S. and internationally in London and Pune, India.

Securisyn Medical is an innovative medical technology and solutions company dedicated to enhancing ventilated patient safety, preventing unplanned extubation and its associated complications, providing peace of mind for patients, their families, and practitioners, and decreasing healthcare costs through ethical, profitable, and sustainable business practices. The company is focused on collaborating with stakeholders around the world to eliminate preventable deaths related to airway management.

NewCompliance empowers caregivers to significantly improve healthcare quality and safety. It collaborates with a number of partners, including Stryker, Medtronic, Skytron, and Philips. Through its innovative solutions, the company strives to empower medical personnel all over the world to optimize safety, efficiency, and satisfaction as a market leader in interoperable IT platforms. Its ACTIQ platform, for example, provides predictive dashboarding and analytics solutions to caregivers. Departments of surgery, emergency care, and intensive care. It enables them to improve hospital safety, efficiency, and patient satisfaction throughout the surgical patient journey.

FundamentalVR have been working with leading pharmaceutical companies to combine virtual and mixed reality with haptic feedback using their ‘FeelRealVR’ platform to create simulated surgical procedures to help educate and train healthcare professionals. The company works at the nexus of haptics, machine learning, and immersive technologies (XR). FundamentalVR was established in 2012 by Chris Scattergood in London, England.

Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.  Eko exists to ensure all patients have access to early heart and lung disease detection that improves and extends their lives.

The Safely App lets potential partners share their verified STD and COVID status in a way that's trusted, private, and secure. More than an app, Safely is a movement to disrupt the spread of STD's and make the world a safer (and more fun) place to be.  Behind it's sexy exterior, Safely is a fully vertically integrated healthcare company with partnerships and proprietary integrations with many of the world's leading healthcare companies, including Quest, Labcorp Mayo Clinic, EPIC, CVS, and more.  SAFE works in partnership with the CDC, many of the world's top nonprofit organizations and influencers, plus social media platforms and dating apps, to empower this and future generations to know and show their status.

GYANT is a digital front door solution for health systems that uses AI to navigate patients to the right care setting and relevant in-network resources. GYANT helps health systems implement digital patient journeys to effectively capture new patients, efficiently serve existing ones, and drive process automation across the enterprise.

Pendulum Therapeutics believes therapies developed using evidence-based microbiome science and DNA sequencing can help heal the body from within. Armed with 13 patents and 42 pending, the company introduced its flagship product Pendulum Glucose Control, a medical probiotic, in 2020 and demonstrated its efficacy in lowering blood sugar spikes and reducing A1C in a published clinical trial. Founded in 2013 by a diverse team of scientists with deep microbiology, biochemistry, computational, and clinical expertise, Pendulum has raised $111 million to date from Meritech Capital, Sequoia Capital, True Ventures, Khosla Ventures, AME Cloud Ventures and Mayo Clinic among others. Pendulum Therapeutics is headquartered in San Francisco.

GIBLIB is a California-based company and is the ''Netflix'' of Medical Education. It is a place for surgeons to share medical lectures and surgical videos. Founded in 2015, GIBLIB is headquartered in Los Angeles, California.

StemoniX is a biotechnology company that focuses on stem cell technologies to meet the demands of drug discovery and personalized medicine. StemoniX is revolutionizing the production, growth, and development of stem cell and stem cell technologies.  It was founded in 2014 and headquartered in Maple Grove, Minnesota.

Rheostat’s mission is to invent novel treatments for neurodegenerative disease through modulation of mitophagy and autophagy. They believe that the degradation of toxic cellular components, whether they are damaged organelles or aggregated proteins, is a fundamental node of biology.  Mutations that impair these clearance pathways cause multiple neurodegenerative diseases, many of which are associated with cognitive impairment. They aim to leverage our understanding of these critical pathways to discover and develop novel small molecules that will restore cellular balance and treat neurodegenerative and rare diseases.

Ambient Clinical Analytics is the creator of a software platform designed for data assimilation, communication and analytics. It is based on decision support tools initially deployed in the intensive care unit (ICU) or emergency department of hospitals. Our software consists of algorithms that mine data from electronic medical records (EMR). It then presents that data to the physicians and nurses so they may facilitate real-time clinical decision making and care delivery. These products are positioned as add on applications that are designed to easily integrate with the current major EMR providers.

Helix is the leading population genomics company working at the intersection of clinical care, research, and genomics. Its end-to-end platform enables health systems, life sciences companies, and payers to advance genomic research and accelerate the integration of genomic data into clinical care. Powered by one of the world's largest CLIA / CAP next-generation sequencing labs and its proprietary Exome+™ assay, Helix supports all aspects of population genomics including recruitment and engagement, clinically actionable disease screening, return of results, and basic and translational research.

Helixis, Inc. is a company that develops low-cost molecular diagnostic products.

Qrativ is a developer of a drug purposing platform designed to reinvent the way treatments for diseases with unmet medical need are discovered and developed. The company's platform ,Darwin.ai, identifies new uses for existing molecules for diseases with unmet medical need and uses machine learning and artificial intelligence for research and development, enabling patient to get treatments for diseases for which drugs are not available in the market.

DayTwo is a precision nutrition company that uses food as medicine to enable a path to remission for metabolic diseases including diabetes, prediabetes, clinical obesity, and NAFLD.  DayTwo's groundbreaking scientific discovery, published in CELL (2015) and JAMA (2019) determined that people respond differently to the same food, thus knowing what food “works” for each person is crucial to an effective care plan.  DayTwo uses gut microbiome sequencing (stool sample, akin to Cologuard) to create Food Prescriptions™ for each patient which balance blood sugar levels, improve energy, manage hunger, and help members lose weight.  DayTwo virtual care solution is delivered through Certified Diabetes Care and Education Specialists and Registered Dietitians using a digital app to track progress and communicate with members.

AliveCor has a device and application that will turn any smartphone into a clinical-quality electrocardiogram (ECG) recorder. AliveCor is pioneering the creation of FDA-cleared 'machine learning' techniques to enable proactive heart care and is recognized around the world for transforming cardiac care. It specializes in the fields of healthcare, mobile device, and medicine. It was founded in 2010 and headquartered in Mountain View, California.

Sensely is a developer of avatar and chatbot-based platform designed to assist insurance plan members and patients. The company's platform leverages conversational interfaces and provides virtual assistant solutions to insurance companies, pharmaceutical clients, and hospital systems worldwide, enabling enterprises to converse with their members in an entirely new way, combining the empathy of human conversation with the efficiency and scalability of the technology.

Unity Biotechnology designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells; and designs senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected.

Chrono Therapeutics (CHRONO) is a pharmaceutical company founded in 2004 with a vision of transforming disease and addiction management to become the market leader in programmable passive transdermal drug delivery (TDD) that offers real-time behavioral support. Chrono’s executive leadership combines years of professional experience and personal passions for developing life-saving medical products. Steeped with years of experience in product development, science, R&D an understanding of the consumer smoking cessation market, FDA approval experience and bringing life-saving products to market, the team represents a wide-array of knowledge that combined can help address the serious epidemic of smoking.

Second Genome’s mission is to transform lives with medicines developed through innovative microbiome science. Second Genome has built a novel platform for microbiome drug discovery. Second Genome has completed more than 400 microbiome studies, analyzing more than 75,000 samples, for internal R&D, as well as for external partners across government, academia, pharmaceutical, nutrition and industrial companies. The team leverages its microbiome analysis platform with its partners’ specific expertise to generate insightful findings that can accelerate research programs by elucidating the role of the microbiome in human health conditions, agriculture, animal health and other industries. The company has established a pipeline of therapeutic products for the treatment of inflammation and metabolic diseases.

As the cost of next-generation sequencing technology continues to drop, this has created an environment where molecular tumor profiling is more accessible than ever before. Despite these advances, there remains a challenge: the ability to analyze and accurately interpret the overwhelming amount of genomic and therapeutic data now available via next generation sequencing.  Lifecode is dedicated to translating and presenting this new information in a meaningful way for patients, payers and providers. Towards this end Lifecode has built an exceptional team of talented individuals with expertise in data science, software engineering, computational biology, bio-informatics, machine learning, curation science, molecular biology, and pathology.	  With funding from both Sequoia Capital and The Mayo Clinic, Lifecode has the DNA of both a software company and a world-class clinical lab.  Their flagship assay, the Lifecode Pan Cancer Somatic Panel is currently being offered on a limited basis to a select number of physicians in the United States.  Lifecode is seeking extremely talented and hardworking individuals who share their passion for genomically driven, personalized cancer care.

Assurex Health is a personalized medicine company dedicated to helping clinicians determine the right medication for individual patients with medical conditions. They provide treatment decision support to healthcare providers for behavioral health and chronic pain conditions.

Ambra Health is a medical data and image management SaaS company. Intuitive, flexible, scalable, and highly interoperable, the Ambra cloud platform is designed to serve as the backbone of imaging innovation and progress for healthcare providers. It empowers health systems such as Memorial Hermann, Stanford Children’s Health, and New England Baptist Hospital as well as radiology practices, subspecialty practices, and clinical research organizations to dramatically improve imaging and collaborative care workflows.

Seres Therapeutics is a clinical-stage biotherapeutic company that develops ecobiotic therapeutic products. They engaged in developing biological drugs which are referred to as ecobiotic microbiome therapeutics. The company is a group of experts in microbiome research and drug development. Its executive team, board of directors, and scientific advisory board have a wealth of experience in the development, regulatory approval, and profitable commercialization of a wide range of therapeutic products.

Better is your Personal Health Assistant. Developed in partnership with Mayo Clinic and Social+Capital Partnership, our service provides free tools and premium access to a team of real Personal Health Assistants so you can spend less time managing the logistics and more time improving your health.

Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.

At Sanguine, our mission is to accelerate translational biomedical research by removing the barriers to patient participation. Through transparent communications, respectful patient support, and appropriate compensation, we keep patients engaged in the research process for a better patient experience and more impactful research biospecimens.

Bluesight solves supply chain inefficiencies and reduces risk by providing actionable analytics for every step of the medication lifecycle. Through the company's suite of Medication Intelligence solutions, Bluesight brings simplicity, visibility, and predictability to the complex world of medication management. More than 1000 U.S. and Canadian hospitals utilize Bluesight solutions to optimize their efficiency.  Bluesight focuses on providing comprehensive, item-level data that empowers providers to make informed, accurate decisions. These solutions include RFID-enabled inventory management, controlled substance diversion prevention software, and medication purchasing optimization.

The Kang San Global Medical Technology (Beijing) Co., Ltd. is a hi-tech enterprise of one for the country at all levels of the hospital to provide advanced specialist inspection services, and the establishment of the National Laboratory of Kang Sheng Global Medical Special Inspection Center. Of the center's national service network belongs wholly owned ...

Anexon, Inc., a pharmaceutical company, develops therapeutics for cardiovascular diseases. The company is based in Cambridge, Massachusetts.

Kardia Health Systems is a healthcare information technology firm offering the delivery of specialty medicine, starting with cardiology. Using Internet technology and a Software-as-a-Service (SaaS) business model, Kardia makes this technology accessible to practices of varying sizes.  Kardia Health Systems, Inc. was incorporated in 2006 and is based in Golden Valley, Minnesota.

NBI Development is an implantable medical device company focused on the development of novel neuromodulation therapies. The company develops neuromodulation, the use of electrical impulses to manage activity in the nervous system.

Mayo Clinic, a not-for-profit medical group practice, provides medical care, research, and education services. It offers medical care services in various specialties, including diabetes and endocrinology, gastroenterology, gynecology, cancer, neurology and neurosurgery, orthopedics, pulmonology, rheumatology, nephrology, urology, and cardiology and heart surgery.

<div>
 
 Mayo Clinic was established in 1889 and is one of the top five hospitals in the US. The hospital ranked first in endocrinology, ENT, gastroenterology, nephrology, and urology treatments in 2019, while serving 1.2 million patients in 50 states, and employing 6,900 physicians and residents and 63,100 support staff. Mayo had the highest number of practitioners among our incumbents.
 
</div>

Mayo Clinic Ventures

A new industry proving that digital connectivity and mental health can co-exist.

Mayo Clinic

Featured Industries

Recent Updates

Exact Sciences partners with Mayo Clinic to provide genomic profiling and hereditary cancer tests to Mayo Clinic patients

apoQlar partners with Mayo Clinic to improve patient care utilizing XR

K Health partners with Mayo Clinic to develop AI solution for heart disease prevention

SimBioSys and Mayo Clinic collaborate to develop solutions for breast cancer

Ayble Health partners with Mayo Clinic to enhance care of chronic GI patients

Naveris partners with Mayo Clinic to launch Dart 2.0 clinical trial

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless